Table 2.
Some examples of clinical trials where heparin is used as a treatment beyond anticoagulant activity (taken from the US National Institute of Health online database http://www.clinicaltrials.gov/ and EU Clinical Trials Register http://www.clinicaltrialsregister.eu/ in Sept., 2012).
| Condition | Intervention | Purpose | Phase | Trial identifier(s) |
|---|---|---|---|---|
| Infertility | Heparin, nadroparin | Heparin increases outcome in poor responders undergoing in vitro fertilisation | Phases 2 and 3 |
NCT01315093
2011-003080-30 |
|
| ||||
| Haemodialysis | Heparin | Evaluates if topically applied heparin to placebo on suitability of constructed primary arteriovenous fistulas | Phase 2 |
NCT01382888
2011-000455-16 |
|
| ||||
| Inhalation burns, smoke inhalation injury | Heparin | Efficacy of nebulised heparin on lung injury score in inhalation burn injury over normal care | Phase 2 | NTC01454869 |
|
| ||||
| Lung cancer | Tinzaparin/enoxaparin | LMWH can inhibit tumour growth and metastasis and enhance survival of patients | Phase 3 |
NCT00475098, NCT00771563, and 2007-007696 |
|
| ||||
| Inflammation | Enoxaparin | Treatment of inflammation in intraocular lens implantation and chronic glomerulonephritis | Phase 4 Phase 3 |
NCT00986076
2005-002989-11 |
|
| ||||
| Adenocarcinoma of the colon | Tinzaparin | LMWH reduction of metastases and recurrence in patients as seen in animal models | Phase 3 | NCT01455831 |
|
| ||||
| Breast, colorectal, Lung, prostate, and venoocclusive cancers | Dalteparin, nadroparin | Assesses if LMWH beyond inhibition of thrombosis improves quality of life over standard treatment | Phases 2 and 3 | NCT00003674, 2005-005336-27 |
|
| ||||
| Vulvodynia | Enoxaparin | LMWH may reduce pain in women with vulvodynia | Phase 2 | NCT00874484 |
|
| ||||
| Ulcerative colitis | Deligoparin | uLMWH may help to reduce inflammation in ulcerative colitis | Phases 2 and 3 | NCT00033943 |
|
| ||||
| Diabetic foot ulcers | Dalteparin | Treatment on chronic foot ulcers due to peripheral arterial occlusive disease in diabetics | Phases 2 and 3 | NCT00765063 |
|
| ||||
| Ovarian cancer | Dalteparin | Assesses the disease response with LMWH over standard therapy | Phase 2 | NCT00239980 |
|
| ||||
| Metastatic Pancreatic cancer | O-Desulphated heparin (ODSH) | Determines if ODSH is efficacious in patients receiving normal therapy | Phase 2 | NCT01461915 |
|
| ||||
| Pregnancy complications | Enoxaparin | Evaluate the efficacy of LMWH on pregnancy outcome in women with previous pregnancy complications | Phase 3 | 2006-004205-26 |
|
| ||||
| Burns | Heparin | Assess analgesic effect of heparin in topical and parenterally treatment | Phase 2 | 2007-004304-12 |
|
| ||||
| Cystic fibrosis | Heparin | Nebulised heparin on easing cystic fibrosis | Phase 2 | 2007-006276-11 |
|
| ||||
| Pulmonary conditions | Heparin, desulfated heparin | Improves lung function in obstructive pulmonary conditions | Phase 2 | 2006-006378-32, 2010-024168-16 |
|
| ||||
| Labour | Nonanticoagulant LMWH | Reducing prolonged labour | Phase 2 | 2006-005839-20 |
|
| ||||
| Microalbuminuria | Sulodexide (LMWH and dermatan sulphate) | Treats microalbuminuria in type 2 diabetes | Phase 3 | 2005-003158-91 |